Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation

Bone Marrow Transplantation

Volumn 25, Issue 7, 2000, Pages 765-769

  Mori, T ^a   Okamoto, S ^a   Matsuoka, S ^a   Yajima, T ^a   Wakui, M ^a   Watanabe, R ^a   Ishida, A ^a   Iwao, Y ^a   Mukai, M ^a   Hibi, T ^a   Ikeda, Y ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CMV antigenemia; Cytomegalovirus; Ganciclovir; Pre emptive therapy; Real time PCR

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; GANCICLOVIR; MELPHALAN; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID; TACROLIMUS; VIRUS ANTIGEN;

ACUTE LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; FEMALE; GASTROENTERITIS; GRAFT VERSUS HOST REACTION; GRANULOCYTOPENIA; HUMAN; HUMAN TISSUE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINITIS; RETROSPECTIVE STUDY; VIRUS REACTIVATION;

EID: 0034070233     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702227     Document Type: Article

References (16)

1. Myers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478-488.
2. Reed EC, Bowden RA, Dandliker PS et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988; 15: 783-788.
3. Goodrich JM, Bowden RA, Fisher L et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173-178.
4. Winston DJ, Bartoni K, Du Mond C et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann Intern Med 1993; 118: 179-184.
5. Goodrich JM, Mori M, Cleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. New Engl J Med 1991; 325: 1601-1607.
6. Schmidt GM, Horak D, Niland JC et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. New Engl J Med 1991; 324: 1005-1011.
7. Boeckh M, Gooley TA, Myerson D et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063-4071.
8. Manteiga R, Martino R, Sureda A et al. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem cell transplantation: a single-center experience. Bone Marrow Transplant 1998; 22: 899-904.
9. Heid CA, Stevens J, Livak KJ et al. Real time quantitative PCR. Genome Res 1996; 6: 986-994.
10. Przepiorka D, Weisdorf D, Martin P et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
11. Kurihara T, Hayashi J, Matusoka T et al. HCMV pp65 antigenemia assay using indirect alkaline phosphatase staining method. Biomed Res 1995; 16: 125-129.
12. Einsele H, Ehninger G, Hebart H et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side-effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815-2820.
13. Ljungman P, Lore K, Aschan J et al. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1996; 17: 583-587.
14. Kanda Y, Chiba S, Suzuki T et al. Time course analysis of semi-quantitative PCR and antigenemia assay for prevention of cytomegalovirus disease after bone marrow transplantation. Br J Haematol 1998; 100: 222-225.
15. Gor D, Sahin C, Prentice HG et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 1998; 21: 597-605.
16. Li C-R, Greenberg PD, Gilvert MJ et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplantation: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971-1979.